http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Bristol-Myers Squibb (BMY) Files Investor Presentation, Letter From Board Related to Pending Celgene (CELG) Deal
-
Bristol-Myers Squibb Files Investor Presentation and Board of Directors Sends Letter to Shareholders Regarding Pending Transaction with Celgene
-
Bristol-Myers Squibb (BMY) Responded to Starboard's Letter, Confident in Combination with Celgene (CELG)
-
Bristol-Myers Squibb Issues Statement in Response to Starboard’s Letter
-
Bristol-Myers Squibb Announces Filing of Definitive Proxy Statement in Connection with Proposed Merger with Celgene
-
Bristol-Myers Squibb (BMY) Provides Update on Pending Transaction with Celgene (CELG), Says Remains on Track to Close in Q3
-
Bristol-Myers Squibb Provides Update on Pending Transaction with Celgene
-
Lyfebulb and Celgene Announce Call for Innovation Challenge Applications to Address Unmet Needs in Multiple Sclerosis
-
Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene (CELG)
-
Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene to Develop Immuno-oncology Therapies
-
Bristol-Myers Squibb (BMY) to Acquire Celgene Corp. (CELG) for Approx. $74B
-
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
-
Sutro Biopharma Inc. (STRO) Secures $10M Milestone Payment from Celgene (CELG)
-
Celgene (CELG) Highlights Initial Clinical Data from Ongoing Phase 1/2 Evolve Trial with Anti-BCMA CAR T Therapy JCARH125
-
Celgene Corporation Announces Initial Clinical Data from Ongoing Phase 1/2 Evolve Trial with Anti-BCMA CAR T Therapy JCARH125 in Relapsed/Refractory Multiple Myeloma at ASH 2018
-
Celgene (CELG) Presents Initial Phase 1/2 Liso-cel Data in Patients with Relapsed/Refractory CLL at ASH 2018
-
Celgene (CELG), Acceleron Pharma (XLRN) Report Results of the Phase 3 MEDALIST Trial Evaluating Luspatercept in Patients with Myelodysplastic Syndromes
-
bluebird bio (BLUE), Celgene Corp. (CELG) Report Initial Data from Ongoing Phase 1 Clinical Study of Next-Generation Anti-BCMA CAR T Cell Therapy bb21217
-
Celgene Corporation Announces Results of AUGMENT Evaluating REVLIMID® In Combination with Rituximab (R²) In Patients with Relapsed/Refractory Indolent Lymphoma At ASH 2018
-
bluebird bio and Celgene Corporation Present Initial Data from Ongoing Phase 1 Clinical Study of Next-Generation Anti-BCMA CAR T Cell Therapy bb21217 in Patients with Relapsed/Refractory Multiple Myel
-
Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 MEDALIST Trial Evaluating Luspatercept in Patients with Myelodysplastic Syndromes at the ASH 2018 Plenary Session
-
Celgene Corporation Announces Initial Phase 1/2 Liso-cel Data in Patients with Relapsed/Refractory CLL, Including Those with High-Risk Disease, Previously Treated with Ibrutinib, at ASH 2018
-
Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 BELIEVE Trial Evaluating Luspatercept in Adult Patients with Beta-Thalassemia at ASH 2018
-
Lyfebulb Partners with Celgene to Inspire Patient-Driven Innovation in the Management of Multiple Sclerosis
-
Results from More Than 100 Abstracts Highlighting Celgene Pipeline Compounds and Therapies to Be Presented at the American Society of Hematology Annual Meeting (ASH)
-
Celgene (CELG) Says First Results of New Data of ABRAXANE in Combination with Atezolizumab Presented at ESMO
-
First Results of New Data of ABRAXANE in Combination with Atezolizumab Presented at ESMO 2018
-
Evotec and Celgene (CELG) Expand IPSC Collaboration to Include Additional Cell Lines
-
Evotec and Celgene (CELG) Enter into Strategic Oncology Partnership
-
Pre-Open Movers 01/22: (BIVV) (JUNO) (ARRY) Higher; (SANM) (TEVA) (TWTR) Lower (more...)
-
Pre-Open Movers 10/26: (MNOV) (BWLD) (TWTR) Higher; (IDRA) (CELG) (NTRI) Lower (more...)
-
Dow, S&P gain but Nasdaq dips as healthcare lags
-
Celgene Corporation (Nasdaq: CELG) to Ring The Nasdaq Stock Market Opening Bell
-
'It's like kumbaya': Trump's genial private meetings with CEOs jar with public attacks
-
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
-
Celgene Corporation, Dana-Farber Cancer Institute and University of Arkansas for Medical Sciences Establish the Myeloma Genome Project
-
Pre-Open Stock Movers 10/27: (PRQR) (OCN) (TWTR) Higher; (CYH) (GNC) (RNWK) Lower (more...)
-
Trading Radar for 10/27: Alphabet (GOOG), Amazon (AMZN), Twitter (TWTR) Ford (F), Baidu.com (BIDU) Report
-
First-Ever Psoriatic Arthritis Awareness Day Aims to Educate on Importance of Early Diagnosis and Treatment
-
Celgene Corporation (Nasdaq: CELG) to Ring The Nasdaq Stock Market Closing Bell
-
Celgene (CELG) Expands Technology Relatinoship with Medidata Solutions (MDSO)
-
Stocks Close Down But Not Before Rip Your Face Off Rally in Beaten Down Names
-
Oral REVLIMID® Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan
-
Celgene (CELG) ABRAXANE Abstracts Presented at San Antonio Breast Cancer Symposium
-
Abstracts at San Antonio Breast Cancer Symposium Highlight ABRAXANE® as a Potential Backbone Therapy in Neoadjuvant and Triple-Negative-Breast Cancer
-
Celgene (CELG), Acceleron (XLRN) Announces Preliminary Results from Two Phase 2 Trials of Luspatercept in Beta-Thalassemia Presented at ASH
-
Celgene and Acceleron Announce New Results from an Investigational Study with Luspatercept in Beta-Thalassemia Presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition
-
Celgene (CELG), AstraZeneca (AZN) Initiative Durvalumab FUSION Program in Hematologic Disorders
-
Celgene in Collaboration with Astrazeneca Announce Initiation of Fusion Clinical Development Program in Immuno-Oncology
-
IMiD® Combination Therapies Form Backbone of Multiple Myeloma Research at ASH
